Symbols

EWTX

Edgewise·NASDAQ

--(--)

Signals Analysis

Bullish signal 2

Bearish signal 1

Consensus Rating "Buy"

Ample Liquidity

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About EWTX

Edgewise Therapeutics, Inc.

A clinical-stage biopharmaceutical company which develops small molecule therapies for rare muscle diseases

Industry

Pharmaceutical

Established Date

Listing Date

03/26/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

146

Fiscal Year Ends

12-31

Website

www.edgewisetx.com

Security Type

Common stock

Office address

1715 38th St., Boulder, CO 80301

Business

Introduction

Edgewise Therapeutics, Inc., was incorporated in Delaware in May 2017. The company is a science-driven biotechnology company focused on developing therapies for serious muscle diseases, with the initial target of rare neuromuscular and heart diseases. Its lead drug candidate sevasemten is an oral small molecule inhibitor that is in late-stage clinical development for the treatment of Duchenne muscular dystrophy and Becker muscular dystrophy.

Company Financials

EPS

EWTX has released its 2025 Q4 earnings. EPS was reported at -0.47, versus the expected -0.44, missing expectations. The chart below visualizes how EWTX has performed over recent quarters, highlighting trends in earnings surprises.